SciSparc Ltd., a foreign private issuer, reported on February 12, 2024, that it received a termination notice from Dekel Pharmaceuticals Ltd. on February 5, 2024, effectively ending the license agreement between the two companies. The agreement, originally signed on May 20, 2015, and subsequently amended, granted SciSparc an exclusive, worldwide license to certain Dekel technology. Dekel alleges that SciSparc breached material contractual obligations by failing to provide required reports on the licensed products. SciSparc disputes these allegations and plans to defend itself vigorously while assessing the potential impact on its business. The termination and ongoing dispute may have implications for SciSparc's operations and its relationship with Dekel.

SciSparc Ltd., a foreign private issuer, reported on February 12, 2024, that it received a termination notice from Dekel Pharmaceuticals Ltd. on February 5, 2024, effectively ending the license agreement between the two companies. The agreement, originally signed on May 20, 2015, and subsequently amended, granted SciSparc an exclusive, worldwide license to certain Dekel technology. Dekel alleges that SciSparc breached material contractual obligations by failing to provide required reports on the licensed products. SciSparc disputes these allegations and plans to defend itself vigorously while assessing the potential impact on its business. The termination and ongoing dispute may have implications for SciSparc's operations and its relationship with Dekel.